100 filings
Page 3 of 5
6-K
4q92gvzfm029zmwig
6 Mar 23
Opthea To Participate in Fireside Chat at Oppenheimer’s 33rd Annual Healthcare Conference
6:02am
6-K
wm5h9c 86ju
23 Feb 23
Current report (foreign)
6:03am
6-K
7b92mplq3g a9
13 Feb 23
Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis® for wet AMD Published in the Journal Ophthalmology
6:03am
6-K
5wk2lo9pn5
6 Feb 23
Opthea To Present at SVB Leerink Global Biopharma Conference
6:02am
6-K
e11qsj kkv1ugefe1h
30 Jan 23
Opthea To Present at Sequire Biotechnology Conference
6:02am
6-K
lp2xr
11 Jan 23
Current report (foreign)
6:02am
6-K
pjd8364f18fxb
12 Dec 22
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
6:04am
6-K
462f5mnna5iu x6v0op
6 Dec 22
Current report (foreign)
6:02am
6-K
iz2io0u3hfok
16 Nov 22
Current report (foreign)
4:18pm
6-K
f9dzo ud5o7x
10 Nov 22
Opthea to Present at Jefferies London Healthcare Conference
4:17pm
6-K
ovkbx pt0y3rgnawjas
24 Oct 22
Current report (foreign)
6:01am
6-K
yq6l 1xo8vfmcw7xx44
26 Sep 22
Market Announcements Office
4:15pm
6-K
jga8ki k15
30 Aug 22
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
7:02am
6-K
9vg31k
26 Aug 22
Notice of Extraordinary General Meeting and Explanatory Notes
4:31pm
6-K
sw1yv1d
25 Aug 22
Current report (foreign)
4:30pm
6-K
nyo0b2xhs7jlng 6t
15 Aug 22
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
6:08am
6-K
inbfk
11 May 22
Opthea To Present at Upcoming Investor Conferences
6:03am
6-K
3szx30
10 May 22
Current report (foreign)
6:02am
6-K
n56tonmx3pp lx88diu
5 May 22
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022
6:02am
6-K
4861ke
29 Apr 22
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting
6:03am